Skip to main content
UniHealth

Doctor search

Andrew R Hoffman, MD

Endocrinology · Stanford

NPI 1619924685

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
13
2 carriers
Offices
2

Offices

2 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

13 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Hoffman’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

13 of 13 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence G47300 · Current

Licensed to practise in California · since 1982 · expires 2027-07-31 · Stanford University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$3,183

Medicare paid this office $3,183 for 33 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes11$705$44

Who their Medicare patients are

33 Original Medicare patients in 2024. Average age 72 · Women 39% · Health risk score 2.28. Sicker patients than 9 in 10 peers; the typical endocrinology clinician is at 1.46.

Conditions among them: High blood pressure 75% · Coronary heart disease 48% · Diabetes 39% · Chronic kidney disease 36% · Heart failure 33%.

The office billed $11,388, Medicare allowed $3,992 and paid $3,183; for 44 services of 9 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20243344722.28$11,388$3,183
20231313691.25$6,988$822
20224571671.20$36,826$4,395
20215787671.39$54,736$6,921
20206077681.46$32,586$4,166
20195372661.72$8,231$3,811
20185775651.59$7,125$4,386
20175280631.74$11,894$4,555
20165984661.98$14,513$4,894
20155071671.54$12,395$3,872
20144670691.48$15,168$4,670
20135489641.42$17,502$5,448

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 1 service

Original Medicare services billed in 2023
Short return visit (20+ min)12$732$61

2022: 2 services

Original Medicare services billed in 2022
Return visit (30+ min)26$2,498$81
Short return visit (20+ min)16$803$50

2021: 2 services

Original Medicare services billed in 2021
Return visit (30+ min)36$3,889$83
Short return visit (20+ min)14$817$58

2020: 1 service

Original Medicare services billed in 2020
Return visit (30+ min)34$2,315$55

2019: 2 services

Original Medicare services billed in 2019
Return visit (30+ min)34$2,187$52
Short return visit (20+ min)17$758$40

2018: 2 services

Original Medicare services billed in 2018
Return visit (30+ min)38$2,666$56
Short return visit (20+ min)16$691$43

2017: 2 services

Original Medicare services billed in 2017
Return visit (30+ min)37$2,749$60
Short return visit (20+ min)19$685$31

2016: 2 services

Original Medicare services billed in 2016
Return visit (30+ min)19$1,611$60
Short return visit (20+ min)30$1,588$42

2015: 2 services

Original Medicare services billed in 2015
Return visit (30+ min)25$1,926$57
Short return visit (20+ min)22$983$39

2014: 2 services

Original Medicare services billed in 2014
Return visit (30+ min)26$2,307$62
Short return visit (20+ min)13$500$38

2013: 2 services

Original Medicare services billed in 2013
Return visit (30+ min)24$2,192$59
Short return visit (20+ min)21$1,081$40

Drugs they prescribed that Part D paid

$9,249

Pharmacies billed $9,249 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 40) in 2024. Too few prescriptions to compare fairly with other clinicians.

26 generic and 14 brand-name prescriptions · $9,249 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Omnitrope12$7,537$628

Year by year

Part D prescribing by year
202440120% (0)35%$9,249
202382240% (0)None$20,725
2022467640% (0)None$170,632
2021595640% (0)None$246,922
2020574570% (0)None$215,685
2019535550% (0)None$148,345
2018508560% (0)None$139,917
2017429490% (0)None$112,623
2016405430% (0)None$66,120
2015318350% (0)44%$69,715
2014272370% (0)46%$56,258
2013295390% (0)None$160,332

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 2 drugs

Part D drugs prescribed in 2023
Hydrocortisone23$1,599$70
Levothyroxine26$542$21

2022: 9 drugs

Part D drugs prescribed in 2022
Norditropin Flexpro21$42,764$2,036
Nutropin Aq Nuspin19$25,198$1,326
Testosterone19$7,700$405
Cabergoline33$7,282$221
Hydrocortisone102$6,512$64
Desmopressin Acetate17$5,265$310
Levothyroxine120$2,427$20
Testosterone Cypionate18$742$41
Alendronate22$367$17

2021: 14 drugs

Part D drugs prescribed in 2021
Sandostatin Lar Depot12$54,512$4,543
Norditropin Flexpro19$36,686$1,931
Nutropin Aq Nuspin15$20,107$1,340
Humatrope11$18,921$1,720
Testosterone36$17,031$473
Hydrocortisone125$7,117$57
Cabergoline40$5,431$136
Desmopressin Acetate27$4,693$174
Levothyroxine125$2,864$23
Cortef20$2,794$140
Desmopressin Acetate16$2,707$169
Testosterone Cypionate28$1,831$65
Alendronate19$247$13
Prednisone18$169$9

2020: 12 drugs

Part D drugs prescribed in 2020
Genotropin17$42,096$2,476
Nutropin Aq Nuspin20$26,284$1,314
Testosterone30$18,047$602
Norditropin Flexpro11$16,567$1,506
Cabergoline46$6,677$145
Desmopressin Acetate40$5,767$144
Hydrocortisone98$4,756$49
Levothyroxine127$2,882$23
Cortef16$2,817$176
Testosterone Cypionate43$2,423$56
Alendronate13$175$13
Prednisone17$101$6

2019: 12 drugs

Part D drugs prescribed in 2019
Testosterone33$22,105$670
Norditropin Flexpro13$21,973$1,690
Nutropin Aq Nuspin14$18,169$1,298
Cabergoline66$8,917$135
Desmopressin Acetate42$5,899$140
Hydrocortisone112$4,322$39
Cortef16$3,036$190
Bromocriptine Mesylate12$2,598$216
Levothyroxine86$2,359$27
Testosterone Cypionate23$1,592$69
Prednisone12$190$16
Alendronate18$174$10

2018: 9 drugs

Part D drugs prescribed in 2018
Androgel19$31,717$1,669
Norditropin Flexpro24$28,756$1,198
Cabergoline47$7,113$151
Desmopressin Acetate45$6,518$145
Testosterone11$4,760$433
Hydrocortisone113$4,702$42
Levothyroxine95$2,702$28
Cortef11$2,232$203
Alendronate21$212$10

2017: 13 drugs

Part D drugs prescribed in 2017
Omnitrope16$32,272$2,017
Norditropin Flexpro12$20,124$1,677
Androgel14$19,499$1,393
Desmopressin Acetate35$4,487$128
Hydrocortisone94$3,934$42
Bromocriptine Mesylate17$3,139$185
Cabergoline20$2,380$119
Levothyroxine75$2,330$31
Cortef12$1,454$121
Testosterone Cypionate16$579$36
Alendronate26$189$7
Prednisone15$88$6
Metformin13$23$2

2016: 9 drugs

Part D drugs prescribed in 2016
Nutropin Aq Nuspin13$14,712$1,132
Hydrocortisone76$3,410$45
Cortef17$2,138$126
Levothyroxine97$2,054$21
Desmopressin Acetate21$2,044$97
Cabergoline17$1,613$95
Alendronate35$161$5
Lisinopril11$16$1
Hydrochlorothiazide11$14$1

2015: 7 drugs

Part D drugs prescribed in 2015
Desmopressin Acetate21$3,485$166
Hydrocortisone70$2,911$42
Levothyroxine85$1,877$22
Cortef22$1,848$84
Cabergoline14$1,325$95
Desmopressin Acetate11$1,189$108
Alendronate23$129$6

2014: 7 drugs

Part D drugs prescribed in 2014
Humatrope20$14,885$744
Desmopressin Acetate22$2,713$123
Hydrocortisone53$2,152$41
Cortef24$1,440$60
Levothyroxine82$1,325$16
Cabergoline15$1,192$79
Testosterone Cypionate11$671$61

2013: 12 drugs

Part D drugs prescribed in 2013
Saizen15$40,269$2,685
Genotropin13$12,962$997
Nutropin Aq Nuspin14$11,727$838
Androgel15$9,758$651
Humatrope15$9,407$627
Cabergoline18$3,746$208
Bromocriptine Mesylate19$2,758$145
Hydrocortisone55$2,187$40
Desmopressin Acetate11$1,735$158
Cortef22$1,167$53
Testosterone Cypionate11$845$77
Levothyroxine60$780$13

Money from drug and device companies

$9,355 in 2025

Industry payments by year
202512$9,287$9,355
202313$9,973$9,973
202212$3,875$3,875
2020118$19,550$22,152
2019218$14,610$17,421

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Ascendis Pharma EndocrinologySkytrofa$9,355
2 payments
  • Consulting for Skytrofa · 2025-12-22 · $9,287
  • Meals for Skytrofa · 2025-11-12 · $67
See all 2 published payments
Every published payment
Ascendis Pharma EndocrinologyConsulting · 2025-12-22Skytrofa$9,287
Ascendis Pharma EndocrinologyMeals · 2025-11-12Skytrofa$67
See earlier years (2023, 2022, 2020, 2019)

2023: $9,973

Payments by company in 2023
Ascendis PharmaSkytrofa$9,973
3 payments
  • Consulting for Skytrofa · 2023-10-13 · $930
  • Paid to speak or teach for Skytrofa · 2023-09-06 · $7,596
  • Consulting for Skytrofa · 2023-03-02 · $1,447

2022: $3,875

Payments by company in 2022
Ascendis PharmaSkytrofa$3,875
2 payments
  • Consulting for Skytrofa · 2022-11-10 · $775
  • Consulting for Skytrofa · 2022-10-27 · $3,100

2020: $22,152

Payments by company in 2020
Novo NordiskNorditropin$22,152
18 payments
  • Consulting for Norditropin · 2020-11-24 · $1,360
  • Consulting for Norditropin · 2020-11-24 · $1,360
  • Consulting for Macrilen · 2020-04-09 · $340
  • Travel for Macrilen · 2020-02-11 · $87
  • Consulting for Macrilen · 2020-02-11 · $4,675
  • Consulting for Norditropin · 2020-02-07 · $8,075
  • Meals for Macrilen · 2020-02-07 · $146
  • Consulting for Norditropin · 2020-02-06 · $2,720
  • Meals for Norditropin · 2020-02-06 · $63
  • Travel for Norditropin · 2020-02-06 · $86
  • Travel for Macrilen · 2020-02-06 · $301
  • Travel for Macrilen · 2020-02-06 · $159
  • Travel for Macrilen · 2020-02-06 · $470
  • Meals for Norditropin · 2020-01-30 · $164
  • Travel for Norditropin · 2020-01-29 · $342
  • Travel for Norditropin · 2020-01-29 · $383
  • Travel for Norditropin · 2020-01-29 · $402
  • Consulting for Norditropin · 2020-01-20 · $1,020

2019: $17,421

Payments by company in 2019
Novo NordiskNorditropin$16,921
17 payments
  • Consulting for Norditropin · 2019-12-11 · $340
  • Travel for Norditropin · 2019-12-06 · $180
  • Travel for Norditropin · 2019-12-06 · $297
  • Travel for Norditropin · 2019-12-06 · $450
  • Travel for Norditropin · 2019-12-06 · $25
  • Consulting for Norditropin · 2019-12-06 · $5,015
  • Travel for Norditropin · 2019-12-06 · $225
  • Meals for Norditropin · 2019-12-05 · $50
  • Consulting for Norditropin · 2019-12-05 · $1,360
  • Consulting for Norditropin · 2019-11-22 · $2,040
  • Travel · 2019-06-15 · $559
  • Meals for Norditropin · 2019-05-03 · $21
  • Travel for Norditropin · 2019-05-03 · $221
  • Travel for Norditropin · 2019-05-03 · $562
  • Travel for Norditropin · 2019-05-03 · $131
  • Consulting for Norditropin · 2019-05-03 · $5,355
  • Travel for Norditropin · 2019-05-03 · $88
Eagle PharmaceuticalsNone$500
1 payment
  • Consulting · 2019-02-19 · $500

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
AbbVie Inc. · Androgel · 2020Their institution$14,343

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1619924685
Licence
CA G47300California G47300: Current · expires 2027-07-31
Trained
Stanford University School of Medicine, 1976
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RE0101X (207RE0101X); Internal medicine (207R00000X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2006-05-27
NPI last updated
2024-04-26
NPI record certified
2024-04-26

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 3801 Miranda Ave, Palo Alto, CA, 94304